Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.
Halvas
Elias K
EK
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, S818 Scaife Hall, 3550 Terrace St., Pittsburgh, PA 15261, and Children's Hospital of Los Angeles, CA, USA.
Aldrovandi
Grace M
GM
Balfe
Peter
P
Beck
Ingrid A
IA
Boltz
Valerie F
VF
Coffin
John M
JM
Frenkel
Lisa M
LM
Hazelwood
J Darren
JD
Johnson
Victoria A
VA
Kearney
Mary
M
Kovacs
Andrea
A
Kuritzkes
Daniel R
DR
Metzner
Karin J
KJ
Nissley
Dwight V
DV
Nowicki
Marek
M
Palmer
Sarah
S
Ziermann
Rainer
R
Zhao
Richard Y
RY
Jennings
Cheryl L
CL
Bremer
James
J
Brambilla
Don
D
Mellors
John W
JW
D019380:Anti-HIV Agents / Q000494:pharmacology; D024882:Drug Resistance, Viral / Q000235:genetics*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D025202:Molecular Diagnostic Techniques; D009154:Mutation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D014773:Virology / Q000379:methods*
D019380:Anti-HIV Agents; D054303:HIV Reverse Transcriptase